Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.
复制标题
DOI：
10.1016/j.semcancer.2015.02.006
复制
发表时间：
2015-12
影响因子：
14.5
通讯作者：
Nowsheen S
中科院分区：
文献类型：
--
作者：
Feitelson MA;Arzumanyan A;Kulathinal RJ;Blain SW;Holcombe RF;Mahajna J;Marino M;Martinez-Chantar ML;Nawroth R;Sanchez-Garcia I;Sharma D;Saxena NK;Singh N;Vlachostergios PJ;Guo S;Honoki K;Fujii H;Georgakilas AG;Bilsland A;Amedei A;Niccolai E;Amin A;Ashraf SS;Boosani CS;Guha G;Ciriolo MR;Aquilano K;Chen S;Mohammed SI;Azmi AS;Bhakta D;Halicka D;Keith WN;Nowsheen S
Proliferation is an important part of cancer development and progression. This is manifest by altered expression and/or activity of cell cycle related proteins. Constitutive activation of many signal transduction pathways also stimulates cell growth. Early steps in tumor development are associated with a fibrogenic response and the development of a hypoxic environment which favors the survival and proliferation of cancer stem cells. Part of the survival strategy of cancer stem cells may manifested by alterations in cell metabolism. Once tumors appear, growth and metastasis may be supported by overproduction of appropriate hormones (in hormonally dependent cancers), by promoting angiogenesis, by undergoing epithelial to mesenchymal transition, by triggering autophagy, and by taking cues from surrounding stromal cells. A number of natural compounds (e.g., curcumin, resveratrol, indole-3-carbinol, brassinin, sulforaphane, epigallocatechin-3-gallate, genistein, ellagitannins, lycopene and quercetin) have been found to inhibit one or more pathways that contribute to proliferation (e.g., hypoxia inducible factor 1, nuclear factor kappa B, phosphoinositide 3 kinase/Akt, insulin-like growth factor receptor 1, Wnt, cell cycle associated proteins, as well as androgen and estrogen receptor signaling). This data, in combination with bioinformatics analyses, will be very important for identifying signaling pathways and molecular targets that may provide early diagnostic markers and/or critical targets for the development of new drugs or drug combinations that block tumor formation and progression.
